Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. 1996

J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

OBJECTIVE This study was designed to determine the toxicity, radiographic response rate, and outcome following high-dose thiotepa, etoposide, and autologous bone marrow rescue (ABMR) for young patients with recurrent malignant brain tumors. METHODS Eligibility criteria required adequate renal, hepatic, and pulmonary function, and no bone marrow infiltration. Thiotepa 300 mg/m2 and etoposide 500 mg/ m2 were infused on 3 consecutive days, and autologous bone marrow was infused 72 hours following chemotherapy. RESULTS Forty-five patients with recurrent high-grade brain tumors, aged 8 months to 36 years (median, 8 years), were treated. Seven patients (16%) died of treatment-related toxicities within 56 days of marrow reinfusion. Delayed platelet engraftment occurred in 44% of patients who survived beyond day 56. Of 35 patients with radiographically measurable disease who survived at least 28 days following ABMR, there were two complete responses (CRs) and six partial responses (PRs), for an overall response (CRs plus PRs) rate of 23% (SE = 7%). Objective responses were observed in four of 14 assessable patients with high-grade glioma and in two of six with primitive neuroectodermal tumors (PNETs)/ medulloblastoma. Survival was significantly improved in patients treated with minimal residual disease (P < .0005). Five of 18 patients (28%) with high-grade gliomas remain free of disease at 39+, 44+, 49+, 52+, and 59+ months post-ABMR. CONCLUSIONS The combination of high-dose thiotepa and etoposide has activity against a variety of recurrent childhood brain tumors. These results merit further evaluation in children and young adults with both recurrent and newly diagnosed high-grade brain tumors.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
November 1991, Bone marrow transplantation,
J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
October 1998, Bone marrow transplantation,
J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
August 1990, Journal of neuro-oncology,
J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
February 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
January 1997, European journal of cancer (Oxford, England : 1990),
J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
January 1992, European journal of cancer (Oxford, England : 1990),
J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
November 2021, Journal of pediatric hematology/oncology,
J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
February 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
May 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J L Finlay, and S Goldman, and M C Wong, and M Cairo, and J Garvin, and C August, and B H Cohen, and P Stanley, and R A Zimmerman, and B Bostrom, and J R Geyer, and R E Harris, and J Sanders, and A J Yates, and J M Boyett, and R J Packer
August 1992, Bone marrow transplantation,
Copied contents to your clipboard!